Pagnin Elisa, Semplicini Andrea, Sartori Michelangelo, Pessina Achille C, Calò Lorenzo A
Department of Clinical and Experimental Medicine, Clinica Medica 4, University of Padua, Via Giustiniani 2, 35128 Padua, Italy.
Am J Hypertens. 2005 Sep;18(9 Pt 1):1200-5. doi: 10.1016/j.amjhyper.2005.03.747.
Activation of RhoA/Rho kinase (ROK) pathway by angiotensin II (Ang II) is involved in the pathophysiology of hypertension and remodeling. In Bartter's and Gitelman's syndrome (BS/GS), the short-term and long-term signaling of Ang II are blunted. The BS/GS have also reduced expression and response on Ang II challenge of ROK, which indicate downregulation of RhoA/ROK pathway. As causes for RhoA/ROK downregulation in BS/GS, we hypothesized an alteration at the level of the upstream regulators of RhoA such as reduced expression of Rho guanine nucleotide exchange factor (RhoGEF), which links activation of G protein-coupled receptors to RhoA/ROK signaling or increased guanine nucleotide dissociation inhibitor (RhoGDI), which inhibits dissociation of GDP from GDI maintaining RhoA in an inactive state.
In mononuclear cells of 9 BS/GS and 9 healthy controls (C), we looked at gene and protein expression (reverse transcriptase-polymerase chain reaction (RT-PCR) and Western blot) of RhoA, RhoGEF, and RhoGDI.
In BS/GS RhoA gene and protein expression were not different from C. Also RhoGDI mRNA and protein levels were not different. On the contrary, p115RhoGEF mRNA and protein levels were reduced in BS/GS.
Reduced p115RhoGEF may explain the downregulation of RhoA/ROK pathway in BS/GS. This is the first report of upstream regulators of RhoA level in BS/GS, a human clinical condition characterized by reduced vascular tone regulation. Because BS/GS represent the mirror image of derangements involved in hypertension, the reduced RhoGEF expression in BS/GS underlines a major impact of RhoA/ROK pathway on blood pressure regulation and confirms BS/GS as a good human model for exploring mechanisms involved in the pathophysiology of hypertension and remodeling.
血管紧张素 II(Ang II)激活 RhoA/Rho 激酶(ROK)途径参与高血压和重塑的病理生理过程。在巴特综合征和吉特曼综合征(BS/GS)中,Ang II 的短期和长期信号转导减弱。BS/GS 对 Ang II 刺激的 ROK 表达和反应也降低,这表明 RhoA/ROK 途径下调。作为 BS/GS 中 RhoA/ROK 下调的原因,我们推测 RhoA 上游调节因子水平发生改变,例如 Rho 鸟嘌呤核苷酸交换因子(RhoGEF)表达降低,RhoGEF 将 G 蛋白偶联受体的激活与 RhoA/ROK 信号转导联系起来,或者鸟嘌呤核苷酸解离抑制剂(RhoGDI)增加,RhoGDI 抑制 GDP 从 RhoA 解离,使 RhoA 维持在无活性状态。
在 9 例 BS/GS 患者和 9 例健康对照(C)的单核细胞中,我们检测了 RhoA、RhoGEF 和 RhoGDI 的基因和蛋白表达(逆转录聚合酶链反应(RT-PCR)和蛋白质印迹法)。
在 BS/GS 中,RhoA 基因和蛋白表达与 C 组无差异。RhoGDI 的 mRNA 和蛋白水平也无差异。相反,BS/GS 中 p115RhoGEF 的 mRNA 和蛋白水平降低。
p115RhoGEF 降低可能解释了 BS/GS 中 RhoA/ROK 途径的下调。这是关于 BS/GS 中 RhoA 水平上游调节因子的首次报道,BS/GS 是一种以血管张力调节降低为特征的人类临床病症。由于 BS/GS 代表了高血压相关紊乱的镜像,BS/GS 中 RhoGEF 表达降低突出了 RhoA/ROK 途径对血压调节的主要影响,并证实 BS/GS 是探索高血压和重塑病理生理机制的良好人类模型。